PMID- 30977905
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20210712
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 92
IP  - 8
DP  - 2020 Aug
TI  - Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and 
      total homocysteine levels during herpes zoster.
PG  - 1253-1259
LID - 10.1002/jmv.25484 [doi]
AB  - The risk of herpes zoster (HZ) increases with age and declining immune function. 
      Increased oxidative stress and inflammatory conditions may cause a negative 
      impact on the immune responses. The present study aimed to assess the levels of 
      oxidative/inflammatory stress biomarkers in HZ patients compared with the 
      controls. This case-control study included 43 HZ patients and 47 age-matched 
      controls. Melatonin (MLT), Indole-dioxygenase (IDO), Interleukin-18 (IL-18), 
      Interleukin-6 (IL-6), ferritin, C-reactive protein (hsCRP), and total 
      homocysteine (tHcy) levels were measured and compared in both groups. The 
      significant high levels of IDO, IL-18, IL-6, ferritin, hsCRP, and tHcy, as well 
      as low levels of MLT were found in HZ patients compared with the controls 
      (P < 0.001); these significant differences were also associated with rash and 
      pain severity (P < 0.001). The final logistic regression model with the area 
      under the curve (0.99; 95% confidence interval [CI], 0.98-1.00) showed the 
      association of HZ with decreased level of MLT (odds ratio [OR], 0.95; 95% CI, 
      0.92-0.98; P = 0.007) and increased levels of tHcy (OR, 1.53; 95% CI, 1.06-2.19; 
      P = 0.02). The findings showed increased inflammation-associated oxidative stress 
      in HZ patients. Elevated tHcy levels and reduced MLT levels may be associated 
      with the manifestation of HZ. More investigations are required to confirm the 
      results.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Khazan, Marjan
AU  - Khazan M
AUID- ORCID: 0000-0002-2520-5710
AD  - Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Nasiri, Soheila
AU  - Nasiri S
AD  - Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Riahi, Seyed M
AU  - Riahi SM
AD  - Department of Epidemiology and Biostatistics, Social Determinants of Health 
      Research Center, Faculty of Health, Birjand University of Medical Sciences, 
      Birjand, Iran.
FAU - Robati, Reza M
AU  - Robati RM
AD  - Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Hedayati, Mehdi
AU  - Hedayati M
AD  - Cellular and Molecular Endocrine Research Center, Research Institute for 
      Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190423
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-18)
RN  - 0 (Interleukin-6)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9007-73-2 (Ferritins)
RN  - JL5DK93RCL (Melatonin)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - Female
MH  - Ferritins/blood
MH  - Herpes Zoster/*blood/*immunology
MH  - Herpesvirus 3, Human/immunology
MH  - Homocysteine/blood
MH  - Humans
MH  - Inflammation
MH  - Interleukin-18/blood
MH  - Interleukin-6/blood
MH  - Logistic Models
MH  - Male
MH  - Melatonin/blood
MH  - Middle Aged
MH  - Oxidative Stress
OTO - NOTNLM
OT  - herpes zoster
OT  - homocysteine
OT  - indole-dioxygenase
OT  - interleukins
OT  - melatonin
OT  - oxidative stress
EDAT- 2019/04/13 06:00
MHDA- 2021/07/13 06:00
CRDT- 2019/04/13 06:00
PHST- 2018/12/01 00:00 [received]
PHST- 2019/03/17 00:00 [revised]
PHST- 2019/04/04 00:00 [accepted]
PHST- 2019/04/13 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2019/04/13 06:00 [entrez]
AID - 10.1002/jmv.25484 [doi]
PST - ppublish
SO  - J Med Virol. 2020 Aug;92(8):1253-1259. doi: 10.1002/jmv.25484. Epub 2019 Apr 23.